Key terms
About QURE
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest QURE news
Apr 08
10:20pm ET
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR)
Mar 25
1:55pm ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 25
4:55am ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 21
11:28am ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 04
6:43am ET
uniQure price target lowered to $7 from $10 at Mizuho
Mar 01
12:05pm ET
Positive Outlook for uniQure Backed by Strong Gene Therapy Pipeline and Strategic Advancements
Mar 01
11:59am ET
uniQure price target lowered to $25 from $30 at H.C. Wainwright
Mar 01
1:01am ET
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), uniQure (QURE) and RegenXBio (RGNX)
Feb 29
9:51am ET
Snowflake downgraded and upgraded: Wall Street’s top analyst calls
Feb 29
8:55am ET
Maintaining Hold on uniQure: Balancing Long-Term Potential Against Near-Term Uncertainties
Feb 29
8:52am ET
Goldman downgrades uniQure on uncertain path in Huntington’s
Feb 29
8:48am ET
uniQure downgraded to Neutral from Buy at Goldman Sachs
Feb 29
7:22am ET
RBC Capital Remains a Buy on uniQure (QURE)
Feb 29
5:43am ET
Maintaining Hold on uniQure Amid Regulatory Uncertainty and Financial Considerations
Feb 29
1:02am ET
A New Cause for Concern: uniQure N.V. Adds a New Innovation / R&D Risk
Feb 28
12:45pm ET
Buy Rating Affirmed for uniQure: Promising Gene Therapy Pipeline and Solid Financial Outlook
Feb 28
10:20am ET
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), uniQure (QURE)
Feb 28
7:12am ET
uniQure reports FY23 EPS ($6.47), consensus ($6.31)
Jan 22
1:45pm ET
Buy Rating Affirmed on uniQure’s Advancing Gene Therapy Pipeline and Anticipated Regulatory Progress
Jan 15
8:47pm ET
RBC Capital Reaffirms Their Buy Rating on uniQure (QURE)
Jan 12
5:53am ET
Maintaining Hold on uniQure Amid Regulatory Uncertainty and Prudent Financial Strategy
Jan 11
1:58am ET
Hold Rating on uniQure Amidst FDA Approval Discussions for AMT-130 Gene Therapy
No recent press releases are available for QURE
QURE Financials
Key terms
Ad Feedback
QURE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
QURE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
